BridgeMD
Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.
EU CTIS ID: 2024-513958-29-00
What this study is testing
To assess the feasibility of conducting a trial to determine whether targeting obesity with semaglutide in patients with resistant hypertension improves blood pressure control versus placebo.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Obesity defined as a BMI ≥ 30kg/m2
- Resistant hypertension defined as: o Mean home systolic BP ≥ 130 mmHg measured in duplicate at a minimum of 6 timepoints. o Prescribed three or more anti-hypertensive medications, which should include a diuretic.
- Prescribed three or more anti-hypertensive medications at optimal doses, one of which should include a diuretic.
- Written informed consent to partake and availability for trial duration.
- Adults, aged ≥18 years at the time of signing informed consent.
You likely can't join if
- Comorbidities: Diabetes with a HbA1c ≥53mmol/L or a requirement for insulin treatment or diabetic retinopathy, previous pancreatitis/pancreatic cancer, end stage renal disease (eGFR <15ml/min), congestive heart failure NYHA class IV, limited life expectancy.
- Otherwise considered unsuitable by the principal investigator or their primary doctor.
- Treatment with any GLP-1 RA or any medication for the indication of obesity within the past 90 days before screening.
- Presence or history of chronic pancreatitis or pancreatic cancer.
- An episode of acute pancreatitis within the last 180 days.
- Patients with severe renal impairment (eGFR < 30 ml/min1.73m2) including patients with end-stage renal disease, patients with severe hepatic impairment, congestive heart failure NYHA class IV, limited life expectancy.
See the full eligibility criteria
- Obesity defined as a BMI ≥ 30kg/m2
- Resistant hypertension defined as: o Mean home systolic BP ≥ 130 mmHg measured in duplicate at a minimum of 6 timepoints. o Prescribed three or more anti-hypertensive medications, which should include a diuretic.
- Prescribed three or more anti-hypertensive medications at optimal doses, one of which should include a diuretic.
- Written informed consent to partake and availability for trial duration.
- Adults, aged ≥18 years at the time of signing informed consent.
- Comorbidities: Diabetes with a HbA1c ≥53mmol/L or a requirement for insulin treatment or diabetic retinopathy, previous pancreatitis/pancreatic cancer, end stage renal disease (eGFR <15ml/min), congestive heart failure NYHA class IV, limited life expectancy.
- Otherwise considered unsuitable by the principal investigator or their primary doctor.
- Treatment with any GLP-1 RA or any medication for the indication of obesity within the past 90 days before screening.
- Presence or history of chronic pancreatitis or pancreatic cancer.
- An episode of acute pancreatitis within the last 180 days.
- Patients with severe renal impairment (eGFR < 30 ml/min1.73m2) including patients with end-stage renal disease, patients with severe hepatic impairment, congestive heart failure NYHA class IV, limited life expectancy.
- Diabetes with a HbA1c ≥53mmol/L or a requirement for insulin treatment or diabetic retinopathy.
- Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
- Hypersensitivity to semaglutide, another GLP1-RA, or excipients of Ozempic®/Wegovy®.
- Personal/family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome
- Previous surgery for weight reduction or major gastro-intestinal tract surgery
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.